Platelet-mimicking nanoparticles co-loaded with W

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapy

Background:

• Photodynamic therapy (PDT) and photothermal therapy (PTT) face limitations due to nanoparticle oxidation and tumor hypoxia.
• W18O49 nanoparticles are effective but susceptible to oxidation and require improved tumor delivery.
• Tumor hypoxia significantly hinders the efficacy of oxidative stress-based cancer therapies like PDT.

Purpose of the Study:

• To develop platelet membrane-coated nanocarriers co-loading W18O49 nanoparticles and metformin (PM-W18O49-Met NPs).
• To enhance the stability, tumor accumulation, and therapeutic efficacy of W18O49 nanoparticles for combined PDT and PTT.
• To investigate the role of metformin in alleviating tumor hypoxia and boosting therapeutic outcomes.

Main Methods:

• Fabrication of PM-W18O49-Met NPs using platelet membranes as nanocarriers.
• In vitro and in vivo evaluation of nanoparticle stability, tumor targeting, and therapeutic effects.
• ROS/hypoxia imaging, IR thermal imaging, and PET imaging to assess treatment response.

Main Results:

• Platelet membranes effectively protected W18O49 NPs from oxidation and facilitated tumor accumulation.
• Metformin introduction significantly reduced tumor oxygen consumption, alleviating hypoxia.
• PM-W18O49-Met NPs demonstrated enhanced ROS and heat generation, leading to inhibited tumor growth and induced apoptosis.

Conclusions:

• Platelet membrane nanocarriers provide a robust platform for co-delivering therapeutic agents and overcoming biological barriers.
• The combination of W18O49 NPs and metformin via platelet membranes offers a synergistic approach to enhance PDT and PTT.
• This strategy presents a promising new avenue for effective cancer therapy by addressing nanoparticle limitations and the tumor microenvironment.